Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada

Figure 2

(a) Tornado diagram for incremental cost of Aerobika® OPEP device vs. no PEP/OPEP device. (b) Tornado diagram for incremental effect (QALY) of Aerobika® OPEP device vs. no PEP/OPEP device. Note. C1: cost per severe exacerbation, C2: cost per patient per month if no exacerbation, C3: cost per moderate exacerbation, P1: percentage of severe exacerbation if no Aerobika® device, P2: percentage of severe exacerbation if using Aerobika® device, P3: probability of exacerbation in the first month after exacerbation if no Aerobika® device, P4: probability of exacerbation between the 2nd and 12th months after exacerbation if no Aerobika® device, P5: probability of death among COPD patients with a severe exacerbation, P6: probability of death among patients with COPD (per year), RR1: relative risk of exacerbation in the first month between Aerobika® device and control groups, RR2: relative risk of exacerbation in the 2nd and 12th months between Aerobika® device and control groups, U1: utility score of patients with COPD (on average), U2: utility decrement for severe exacerbation (per month), U3: utility decrement for moderate exacerbation (per month).

(a)

(b)